USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: GENEXPRESS INFORMATICS, INC.
City: Austin
State: TX
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (512) 496-5110

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $479,792.00 6
SBIR Phase II $2,690,638.00 4
STTR Phase I $95,027.00 1

Award List:

Automated Preferential Display for the Analysis of Gene Expression Profiles

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency / Branch: DOD / CBD
Principal Investigator: Robert Chin, President
Award Amount: $69,900.00
Abstract:
"GeneXpress Informatics, Inc. (GXI) and Dr. James P. Chambers of UTSA propose to develop a revolutionary differential gene display technology, called Preferential Display (PD) which will provide for a simplified, cost-effective method to identify thesegenes for use in discovering gene expression… More

Discovering Stress Related Gene Transcript for Bioreactor Monitoring

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: NASA
Principal Investigator: Robert Chin, Principal Investigator
Award Amount: $69,971.00
Abstract:
GeneXpress Informatics, Inc. (GXI) and Dr. James P. Chambers of the University of Texas at San Antonio propose to use GXI's patent pending, Preferential Display (PD) technology to identify and isolate stress-related gene expression transcripts for the use in developing a real-time bioreactor… More

Preferential Display (PD) based PROTECT system

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency / Branch: DOD / USAF
Principal Investigator: Robert Chin, President
Award Amount: $99,998.00
Abstract:
Exposure of humans to chemical or biological warfare agents has been demonstrate to be detected within hours of contact by measuring gene expression levels (profiles) on a genomic scale using microarray chips. While this technology has been shown to bedeployable in the field, the human genomics… More

Preferential Display (PD) based PROTECT system

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency / Branch: DOD / USAF
Principal Investigator: Robert Chin
Award Amount: $749,698.00
Abstract:
During the Phase I, GeneXpress Informatics (GXI) provided proof-of-concept for the Preferential Display (PD) technology. GXI's Preferential Display (PD) technology is a paradigm shift in high throughput gene expression and analysis. The PD technology eliminates redundant sequences found between… More

Non-Invasive Transcranial Doppler Sonogram Device for Detection of Embolic Air in Cerebral Arteries

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: NASA
Principal Investigator: Robert Chin, Principal Investigator
Award Amount: $69,987.00
Abstract:
Technology is needed to provide real-time assessment and evaluation of hematological parameters during prolong space flights and planetary missions. A key hematological parameter is the monitoring and measurement of emboli in the brain especially during Extra-Vehicular Activity (EVA) on planetary… More

Multi-IMmmunotoxicity Assay System (MIMAS)

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency / Branch: DOD / USAF
Principal Investigator: Robert Chin, President
Award Amount: $99,938.00
Abstract:
GeneXpress Informatics, Inc. (GXI) proposes to develop a Multi-IMmunotoxicity Assay System (MIMAS) based upon the Luminex Corporation (Austin, TX) xMAP system, a flexible analyzer based on the principles of flow cytometry. The proposed MIMAS will utilize three core technologies. The first is the… More

Compact Transcranial Doppler (TCD) for Bioastronautics Research

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: NASA
Principal Investigator: Robert Chin, Principal Investigator
Award Amount: $594,571.00
Abstract:
Returning men to the Moon and manned Mars missions will require advanced bioastronanutics research. One possible risk is Decompression Sickness (DCS) resulting from extravehicular activity (EVA), after exposure to habitat conditions that would be generated using available Moon or Martian resources.… More

Multi-analyte Immuno-Magnetic Assay System (MIMAS)

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency / Branch: DOD / USAF
Principal Investigator: Robert Chin, President
Award Amount: $747,163.00
Abstract:
GeneXpress Informatics, Ten X Technology and the University of Texas Health Science Center at San Antonio (UTHSC-SA) has developed and demonstrated a Multi-ImmunoMagnetic Assay System (MIMAS) with a detection limit of 2 attograms/ml for a human IL-15 assay which is 6 orders of magnitude more… More

Development of Biological Obscurants

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency / Branch: DOD / NAVY
Principal Investigator: Robert Chin, President
Award Amount: $69,998.00
Abstract:
The DoD has funded a number of nanotechnology based obscurant projects. Recent studies have shown the potential health and environmental risk associated with nanoparticle exposures. Development of biologically based obscurants could eliminate these shortcomings by providing multi-spectral… More

Development of Biological Obscurants

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency / Branch: DOD / NAVY
Principal Investigator: Robert Chin, President
Award Amount: $599,206.00
Abstract:
In Phase I, GeneXpress Informatics (GXI) and Dr. James P. Chambers of the University of Texas at San Antonio proposed to develop biological obscurants for battlefield applications based on the use of bacteriochlorophylls. Upon completion and presentation of results to MARCORSYSCOM, GXI and Chambers… More

Development of biological based nanoparticles for improved smoke/obscurant formulations

Award Year / Program / Phase: 2012 / STTR / Phase I
Agency / Branch: DOD / ARMY
Research Institution: University of Texas at San Antonio
Principal Investigator: Robert Chin, President – (512) 219-8588
Award Amount: $95,027.00
RI Contact: James P. Chambers
Abstract:
Studies have shown the potential health and environmental hazards associated with hexachloroethane (HC) and terephthalic (TA) smoke/obscurants. In order to avoid using these materials, new chemical formulations are needed to address toxicological concerns and yet still maintain Grenade Figure of… More